G
GenFleet Therapeutics
A developer and researcher of molecular pharmaceuticals targeting cancer treatments
About GenFleet Therapeutics
GenFleet Therapeutics, founded in 2017 and based in Shanghai, is a pioneering biopharmaceutical company focused on the development of innovative drugs. The company operates in the pharmaceutical and biotechnology sector, serving patients worldwide by addressing unmet medical needs. GenFleet's core business model revolves around an integrated platform that spans research and development (R&D), production, and commercialization of novel therapeutics. This approach allows the company to streamline the drug development process, from initial discovery to market launch, ensuring efficiency and effectiveness.
GenFleet primarily targets oncology and immunology, leveraging its expertise to develop cutting-edge treatments. The company has demonstrated its capabilities through successful clinical trials, such as the Phase I clinical trial of GFH018, which showed promising safety and efficacy results. GenFleet collaborates with global partners and utilizes a combination of in-house R&D and strategic alliances to advance its drug pipeline.
Revenue generation for GenFleet comes from multiple streams, including licensing agreements, milestone payments, and eventual product sales. By focusing on high-impact therapeutic areas and maintaining a strong pipeline of drug candidates, GenFleet aims to deliver significant value to its stakeholders and improve patient outcomes globally.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Pudong, China
- Employees
- 15
- Open positions
- None listed
- Dealroom signal
- 74.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | Sep 2025 | $202M | $1.8B | Undisclosed | ↗ |
| SERIES COther financing | Dec 2021 | $75M | $300M | Huagai Capital · Baidu Ventures · Qiaojing Capital · Deyi Capital | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for GenFleet Therapeutics is 3.5K monthly website visits, up 169.2% over the last three months. GenFleet Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Highlight Capital
Series A10 investors entered at this stage
Shenzhen Capital Group
CDH Investments- SCSinopharm Capital
South China Venture Capital
Pan-Lin Asset Management
Lake Bleu Capital
HM Capital
NLVC- LMLinden Asset Management
- SCShanjin Capital
Series B and later8 investors entered at this stage
Huagai Capital
Baidu Ventures- QCQiaojing Capital
- DCDeyi Capital
- SCSu xin Venture Capital
- XIXie Nuo Investment
- ABABCI
- WIWenzhou Investment
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about GenFleet Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See GenFleet Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.